The global stem cell manufacturing market size reached US$ 12.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 19.9 Billion by 2028, exhibiting a growth rate (CAGR) of 8.1% during 2023-2028. Increasing investments in stem cell research, rising chronic disease prevalence, advancements in biotechnology, collaborations between academia and industry, stringent regulations, and expanding awareness of stem cell therapies are stimulating the market growth.
|Market Size in 2022
||US$ 12.3 Billion
|Market Forecast in 2028
||US$ 19.9 Billion
|Market Growth Rate (2023-2028)
Stem cell manufacturing is a highly sophisticated and rapidly evolving field dedicated to the controlled production of stem cells, which possess the unique ability to develop into umpteen specialized cell types within the human body. This process plays a pivotal role in regenerative medicine, drug development, and disease modeling. There are two types of stem cell manufacturing: embryonic stem cell production, derived from early-stage embryos, and induced pluripotent stem cell (iPSC) production, which reprograms adult cells to an embryonic-like state. The advantages of stem cell manufacturing are manifold, as it offers a renewable source of cells for research, drug testing, and potential therapeutic applications.
The global stem cell manufacturing market is influenced by increasing investments in stem cell research and regenerative medicine by governments and private organizations. Additionally, the rising prevalence of chronic diseases and the need for innovative treatment options are propelling the market growth. In line with this, advancements in biotechnology and cell culture techniques and a growing aging population are bolstering the market growth. Stringent regulatory frameworks and ethical considerations and collaborative efforts between academia and industry players for research and development (R&D) initiatives are contributing to the market growth. Apart from this, the increasing awareness and acceptance of stem cell-based therapies among patients and healthcare professionals is augmenting the market growth.
Stem Cell Manufacturing Market Trends/Drivers:
Increasing investments in stem cell research and regenerative medicine
The global stem cell manufacturing market is experiencing a significant upsurge due to the substantial investments pouring into stem cell research and regenerative medicine. Governments and private organizations are channeling resources toward these fields, recognizing their potential to revolutionize healthcare. This driver is fueled by the promising prospects of stem cell therapies in addressing previously untreatable conditions, such as neurodegenerative diseases and spinal cord injuries. These investments support cutting-edge research, the development of advanced manufacturing techniques, and the expansion of clinical trials. As a result, the market witnesses an influx of innovative therapies and products, fostering its growth and establishing it as a pivotal player in the healthcare landscape.
Rising prevalence of chronic diseases and the demand for innovative treatments
Another vital driver propelling the global stem cell manufacturing market is the escalating prevalence of chronic diseases. Conditions like diabetes, heart disease, and autoimmune disorders are on the rise, necessitating novel and effective treatments. Stem cell therapies hold immense promise in addressing these ailments by regenerating damaged tissues and organs. Consequently, the demand for stem cell-based treatments is soaring as patients seek alternatives to traditional approaches. This surge in demand not only drives market growth but also underscores the urgency of advancing stem cell manufacturing techniques to meet the healthcare needs of millions worldwide.
Advancements in biotechnology and cell culture techniques
Advancements in biotechnology and cell culture techniques are revolutionizing the field of stem cell manufacturing. This driver is pivotal in enhancing the efficiency and scalability of stem cell production. Breakthroughs in cell culture technology, such as 3D cell culture systems and bioreactors, enable the cultivation of high-quality stem cells in larger quantities. Additionally, innovations in genetic editing techniques, like CRISPR-Cas9, offer precise control over stem cell characteristics, further expanding their therapeutic potential. These advancements not only streamline the manufacturing process but also ensure the safety and quality of stem cell-based therapies, instilling confidence among healthcare professionals and patients alike.
Stem Cell Manufacturing Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global stem cell manufacturing market report, along with forecasts at the global, regional, and country levels for 2023-2028. Our report has categorized the market based on product, application, and end user.
Breakup by Product:
- Bioreactors and Incubators
- Cell Sorters
- Stem Cell Lines
- Hematopoietic Stem Cells (HSC)
- Mesenchymal Stem Cells (MSC)
- Induced Pluripotent Stem Cells (iPSC)
- Embryonic Stem Cells (ESC)
- Neural Stem Cells (NSC)
- Multipotent Adult Progenitor Stem Cells
Consumables dominate the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes consumables (culture media and others), instruments (bioreactors and incubators, cell sorters, and others), and stem cell lines (hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), induced pluripotent stem cells (iPSC), embryonic stem cells (ESC), neural stem cells (NSC), and multipotent adult progenitor stem cells). According to the report, consumables represented the largest segment.
The consumables segment within the stem cell manufacturing market is experiencing robust growth due to the increasing adoption of stem cell-based research and therapies, necessitating a constant supply of consumables, including cell culture media, reagents, and growth factors. As research in this field expands, so does the demand for these essential materials. Moreover, the growing number of stem cell clinical trials and applications in regenerative medicine fuels the consumption of consumables. Clinical research and therapy development require a consistent and reliable source of high-quality consumables to ensure the safety and efficacy of stem cell-based treatments. In line with this, technological advancements in the production of consumables are driving growth. Innovations in the formulation of specialized culture media and the development of serum-free and xeno-free alternatives enhance the efficiency of stem cell culture, making them increasingly attractive to researchers and manufacturers. Apart from this, stringent regulatory standards and quality control measures necessitate the use of certified consumables, further boosting market growth as manufacturers adhere to these requirements.
Breakup by Application:
- Research Applications
- Life Science Research
- Drug Discovery and Development
- Clinical Application
- Allogenic Stem Cell Therapy
- Autologous Stem Cell Therapy
- Cell and Tissue Banking Applications
Research applications dominate the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes research applications (life science research and drug discovery and development), clinical application (allogenic stem cell therapy and autologous stem cell therapy), and cell and tissue banking applications. According to the report, research applications represented the largest segment.
The growth of the research applications segment within the stem cell manufacturing market is underpinned by the relentless pursuit of scientific knowledge and breakthrough discoveries in stem cell biology fuels the demand for stem cells in research. Stem cells serve as essential tools for investigating various biological processes, disease mechanisms, and potential therapeutic avenues. Researchers across diverse fields, including regenerative medicine, developmental biology, and drug development, rely on stem cells to advance their studies. Moreover, the increasing funding and grants allocated to stem cell research bolster this segment's growth. Governments, private institutions, and nonprofit organizations recognize the transformative potential of stem cell research and provide financial support to drive innovation. Additionally, technological advancements in stem cell culture techniques, genetic editing, and cell characterization tools enhance the efficiency and accuracy of research applications. These advancements enable researchers to work with a broader range of stem cell types and manipulate them with precision, further expanding the scope of research possibilities.
Breakup by End User:
- Pharmaceutical & Biotechnology Companies
- Academic Institutes, Research Laboratories and Contract Research Organizations
- Hospitals and Surgical Centers
- Cell and Tissue banks
Pharmaceutical & biotechnology companies dominate the market
The report has provided a detailed breakup and analysis of the market based on the end user. This includes pharmaceutical & biotechnology companies, academic institutes, research laboratories and contract research organizations, hospitals and surgical centers, cell and tissue banks, and others. According to the report, pharmaceutical & biotechnology companies represented the largest segment.
The growth of pharmaceutical and biotechnology companies is propelled by the continuous expansion of the global population and the aging demographic trends. With an aging population, the demand for healthcare services, medications, and innovative therapies rises, providing a substantial market for pharmaceutical and biotechnology companies to cater to. Moreover, the increasing prevalence of chronic diseases, including cardiovascular disorders, cancer, and diabetes, necessitates ongoing research and the development of new pharmaceutical solutions. These companies play a pivotal role in creating advanced drugs and therapies to combat these health challenges. Furthermore, advancements in biotechnology, including gene therapy, precision medicine, and biopharmaceuticals, are shaping the industry. Pharmaceutical and biotechnology firms are at the forefront of these innovations, driving growth through the development of cutting-edge treatments and personalized medicine approaches.
Breakup by Region:
- North America
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
North America exhibits a clear dominance, accounting for the largest stem cell manufacturing market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The North American region is experiencing robust growth in the stem cell manufacturing market, propelled by the substantial government funding and private investments in stem cell research and regenerative medicine. These financial commitments support cutting-edge research, clinical trials, and the development of advanced manufacturing techniques. Moreover, the prevalence of chronic diseases, such as diabetes, heart disease, and neurodegenerative disorders, is on the rise in North America. Stem cell therapies offer innovative solutions to address these conditions, fueling demand for their production. In line with this, the region boasts a highly developed biotechnology sector, leading to significant advancements in cell culture techniques and bioprocessing technologies. This ensures efficient and scalable stem cell production, strengthening the industry's foothold in North America. Furthermore, regulatory frameworks in North America provide a conducive environment for stem cell research and clinical trials, fostering growth and innovation. Collaborative efforts between academic institutions and industry players, along with growing public awareness of the potential of stem cell-based treatments, are additional drivers.
The competitive landscape within the global stem cell manufacturing market is characterized by a dynamic interplay of numerous players, each vying to establish their prominence and contribute to the industry's growth. These entities span a spectrum of organizations, including research institutions, biotechnology companies, pharmaceutical giants, and contract manufacturing organizations. Their diverse backgrounds and resources contribute to a multifaceted ecosystem that fosters innovation and advancements in stem cell manufacturing. Key competitive strategies encompass research and development efforts to enhance manufacturing processes, scale up production, and improve the quality and safety of stem cell-based therapies. Additionally, partnerships and collaborations between these players are common, facilitating knowledge sharing and the development of cutting-edge technologies. Regulatory compliance and adherence to ethical standards are pivotal in maintaining credibility within the market. Moreover, market participants often engage in marketing and educational initiatives to increase awareness of stem cell therapies among healthcare professionals and the public, further expanding their reach.
The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
- Anterogen Co. Ltd.
- Becton Dickinson and Company
- Bio-Rad Laboratories Inc.
- Bio-Techne Corporation
- Corning Incorporated
- FUJIFILM Holdings Corporation
- Lonza Group AG
- Merck KGaA
- Sartorius AG
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
- In July 2023, Bio-Techne Corporation announced the complete acquisition of Lunaphore Technologies SA, a leading developer of fully automated spatial biology solutions. Bio-Techne and Lunaphore are combining forces to accelerate their spatial biology leadership position in translational and clinical research markets.
- In July 2019, Bio-Rad Laboratories, Inc. announced the launch of its scATAC-Seq solution, a single-cell assay for transposase-accessible chromatin using sequencing.
- In June 2023, Becton Dickinson and Company announced to invest US$ 80 million in the construction of its third plant in Ciudad Juarez.
Stem Cell Manufacturing Market Report Scope:
|Base Year of the Analysis
|Scope of the Report
||Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
- End User
- Consumables: Culture Media, Others
- Instruments: Bioreactors and Incubators, Cell Sorters, Others
- Stem Cell Lines: Hematopoietic Stem Cells (HSC), Mesenchymal Stem Cells (MSC), Induced Pluripotent Stem Cells (iPSC), Embryonic Stem Cells (ESC), Neural Stem Cells (NSC), Multipotent Adult Progenitor Stem Cells
- Research Applications: Life Science Research, Drug Discovery and Development
- Clinical Application: Allogenic Stem Cell Therapy, Autologous Stem Cell Therapy
- Cell and Tissue Banking Applications
|End Users Covered
||Pharmaceutical & Biotechnology Companies, Academic Institutes, Research Laboratories and Contract Research Organizations, Hospitals and Surgical Centers, Cell and Tissue banks, Others
||Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Anterogen Co. Ltd., Becton Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Corning Incorporated, FUJIFILM Holdings Corporation, Lonza Group AG, Merck KGaA, Sartorius AG, Takara Bio Inc., Thermo Fisher Scientific Inc., etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Benefits for Stakeholders:
- IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the stem cell manufacturing market from 2017-2028.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the global stem cell manufacturing market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the stem cell manufacturing industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.